Author: cnadmin

Le nouveau package est une extension d’une collection existante de plus de 100 modèles de solutions qui permettent aux utilisateurs de Laserfiche de télécharger des diagrammes de processus, des flux de travail, des champs de modèles et des rapports, qui peuvent tous être configurés pour répondre aux exigences opérationnelles spécifiques d’une organisation pour un déploiement rapide de la solution.

Linda Ding, directrice principale du marketing stratégique chez Laserfiche, a déclaré : « Laserfiche s’est engagé à soutenir les organisations de tous les secteurs d’activité dans leur réponse rapide à la pandémie. Nous avons travaillé avec des clients innovants, des leaders de l’industrie et des partenaires technologiques pour développer des modèles de flux de travail à faible code qui peuvent être déployés rapidement, dans le but d’accroître l’accessibilité des services et la visibilité des procédures de sécurité lorsque les employés, les clients, les étudiants et les électeurs en ont le plus besoin, et de redonner du temps aux dirigeants des organisations pour qu’ils se concentrent sur le bien-être de leurs communautés et l’avenir de leur entreprise. »

Le package comprend trois catégories d’automatisation des processus que les utilisateurs peuvent utiliser dans des contextes variés : intervention d’urgence à court terme, modernisation des flux de travail à moyen terme et transformation numérique à long terme. Les premières de ces nouvelles solutions sont disponibles dès maintenant, et des versions supplémentaires sont prévues pour août et octobre 2021. La version initiale comprend les solutions suivantes :

• Le rapport quotidien des symptômes des employés permet un dépistage plus rapide des employés et favorise la sécurité au travail. La solution permet aux employés de soumettre un rapport quotidien de symptômes en ligne avant de commencer à travailler pour la journée. Un représentant des ressources humaines est averti par courrier électronique si un employé a une température élevée, signale des symptômes ou a été en contact avec une personne diagnostiquée avec le COVID-19. Ces employés sont alors informés par un e-mail automatisé qu’ils doivent rester chez eux et se reposer ou qu’il leur est recommandé de travailler à distance.
• L’enquête sur l’expérience du travail à domicile soutient les efforts continus des employeurs pour surveiller le bien-être des employés qui travaillent à distance. Les employeurs peuvent utiliser cette solution d’enquête pour évaluer dans quelle mesure leurs employés s’adaptent au travail à domicile, ce qui fonctionne bien et ce qui pourrait être amélioré. Les questions de l’enquête peuvent être facilement adaptées aux besoins de l’organisation.
• Le suivi de l’inventaire et la demande d’équipement permettent aux équipes informatiques de suivre le matériel fourni aux employés distants et de gérer l’inventaire des équipements. Pour suivre le matériel initialement utilisé au bureau, les employés fournissent les informations associées à leur matériel, comme le numéro d’identification de l’appareil, via un formulaire électronique. Ce formulaire peut également être utilisé pour demander du matériel supplémentaire. Lorsqu’une demande de matériel supplémentaire est soumise, un représentant informatique est automatiquement désigné pour attribuer le matériel à l’employé.
• Le questionnaire de retour au travail permet aux employeurs de recueillir les informations nécessaires, telles que les symptômes des employés et le calendrier de retour au travail prévu, afin d’informer et de soutenir la stratégie de réouverture de l’entreprise. Sur la base des réponses des employés, ceux-ci peuvent être affectés à une cohorte ou à une phase spécifique qui s’aligne sur les conseils des autorités sanitaires locales, correspond à votre stratégie de réouverture et permet à votre organisation de gérer la capacité des bureaux.
• La demande de congé COVID-19  permet de se conformer à la loi Families First Coronavirus Response Act, qui prévoit que les employés bénéficient d’un congé de maladie payé ou d’un congé médical et familial étendu pour des raisons liées au COVID-19. Un employé peut soumettre une demande de congé par le biais d’un formulaire en ligne ; elle est ensuite automatiquement assignée à un représentant des ressources humaines pour examen et approbation. Un e-mail automatique informe l’employé de l’approbation ou du refus de sa demande.

En plus de permettre le déploiement rapide de solutions automatisées, le package Digital Reopening donne aux organisations les outils pour suivre les demandes et traiter les données, ce qui permet une optimisation continue. Des organisations du monde entier ont tiré parti de Laserfiche tout au long de la pandémie, en développant une infrastructure informatique et des plans de continuité des activités robustes, et en transformant l’expérience numérique des employés et des clients lors de perturbations majeures. Pour en savoir plus sur la façon dont les organisations ont utilisé Laserfiche tout au long de la pandémie et dans la planification de l’avenir, visitez la page de ressource Digital Reopening de Laserfiche.

Notes à l’intention des rédacteurs

À propos de Laserfiche

Laserfiche est le principal fournisseur de logiciels à la demande offrant des solutions de gestion intelligente du contenu et d’automatisation des processus opérationnels. Grâce à de puissants flux opérationnels, à des formulaires électroniques ainsi qu’à la gestion et l’analyse de documents, la plate-forme Laserfiche® accélère les processus d’affaires, ce qui permet aux dirigeants de se concentrer sur la croissance globale de leur entreprise.

Laserfiche est une pionnière en matière de gestion du contenu des entreprises pour éliminer l’utilisation du papier au bureau. Aujourd’hui, son approche de développement axée sur le cloud intègre les innovations en matière d’apprentissage machine et d’IA, afin de permettre aux entreprises de plus de 80 pays de passer au numérique. Les clients issus de tous les horizons – gouvernement, éducation, services financiers, soins de santé, fabrication – font appel à Laserfiche pour accroître leur productivité, prendre de l’expansion et offrir des expériences client axées sur le numérique.

Basés dans différents bureaux aux quatre coins du globe, les employés de Laserfiche s’engagent à réaliser la vision de l’entreprise : renforcer l’autonomie des clients et inspirer les gens à repenser comment la technologie peut transformer leurs vies.

Pour communiquer avec Laserfiche :

Blog de Laserfiche  |  Twitter  |  LinkedIn  |  Facebook

Logo : https://mma.prnewswire.com/media/626078/Laserfiche_Logo.jpg 

The new package is an expansion to an existing collection of over 100 solution templates that allow Laserfiche users to download process diagrams, workflows, template fields and reports, all of which can be configured to fit an organisation’s specific operational requirements for rapid solution deployment.

Linda Ding, senior director of strategic marketing at Laserfiche said: “Laserfiche is committed to supporting organisations across industries in their quick response to recovery from the pandemic. We worked with innovative customers, industry leaders and technology partners to develop this package’s low-code workflow templates that can be deployed quickly, with the goal of increasing accessibility of services and visibility into safety procedures when employees, customers, students and constituents need them most; and reclaiming time for organisational leaders to focus on the well-being of their communities, and the future of their enterprise.”

The package includes three categories of process automation users can utilise for a variety of contexts: short-term emergency response, medium-term workflow modernisation, and long-term digital transformation. The first of these new solutions are available now, with additional releases planned for August and October 2021. The initial release includes the following solutions:

• Daily employee symptom report enables faster pre-screening for employees and supports continued safety at work. The solution allows employees to submit a daily symptom report online before starting work for the day. A human resources representative is notified by email if an employee has an elevated temperature, reports any symptoms or has come in contact with anyone diagnosed with COVID-19. These employees are then notified via automated email to stay home and rest or are recommended to work remotely.
• Work from home experience survey supports employers’ ongoing effort to monitor employee well-being while working remotely. Employers can use this survey solution to assess how well their employees are adjusting to working from home, what works well, and what could be improved. Survey questions can be easily tailored to organisational needs.
• Inventory tracking and equipment request enables IT teams to track hardware provided to remote employees and manage equipment inventory. To track hardware originally used in-office, employees provide information associated with their hardware, like device ID number, via an electronic form. The form can also be used to request additional equipment. When a request is submitted for additional hardware, an IT representative is automatically designated to assign equipment to the employee.
• Return to work questionnaire allows employers to collect needed information such as employee symptoms and intended return to work schedule to inform and support organisation’s reopening strategy. Based on employee answers, they can be assigned to a specific cohort or phase that aligns with guidance from local health officials, corresponds to your reopening strategy and enables your organisation to manage in-office capacity.
• COVID-19 time-off request helps support compliance with the Families First Coronavirus Response Act to provide employees with paid sick leave or expanded medical and family leave for reasons related to COVID-19. An employee can submit a time-off request via an online form; it is then automatically assigned to a human resources representative for review and approval. An automated email notifies the employee whether the request is approved or denied.

In addition to enabling the rapid deployment of automated solutions, the Digital Reopening package gives organisations the tools to track requests and process data, allowing for continuous optimisation. Organisations around the world have leveraged Laserfiche throughout the pandemic, developing robust IT infrastructure and business continuity plans, and transforming the digital experience for employees and customers during major disruptions. To learn more about how organisations have used Laserfiche throughout the pandemic and in planning for the future, visit Laserfiche’s Digital Reopening Resource Page.

Notes to Editors

About Laserfiche

Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.

Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organisations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.

Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.

Connect with Laserfiche:

Laserfiche Blog | Twitter | LinkedIn | Facebook

Logo – https://mma.prnewswire.com/media/626078/Laserfiche_Logo.jpg

George Tjungurrayi Ward, Tingarri, acrylic on linen, 300x760mm 2021

Rita and Monica Watson at Ninuku Arts

DALLAS, Aug. 2, 2021 /PRNewswire/ — The Vision Impact Institute applauds the UN General Assembly’s adoption of the Vision for Everyone: accelerating action to achieve the Sustainable Development Goals resolution. A major step forward for vision correction, this resolution commits the international community to improving vision for 1.1 billion people living with preventable vision loss by 2030.

This topic is timely as societies cope with the fallout of the COVID-19 pandemic in terms of:

• Children’s Education – The connection between vision and learning is crucial, as eighty percent of learning is visual. Yet, with increased digital learning, children are experiencing vision changes such as myopia and eye strain from more screen time and less time outdoors.

• Road Safety – With up to 90% of the information needed for safety on the road coming through the eyes, good vision is a critical factor for safer mobility. This becomes more important as workers return to office buildings and businesses.

• Gender Equity – Research suggests that 55% of people with vision loss are women and girls. Women can also face stigmas when it comes to wearing glasses. This burden, compounded with the burden that the COVID-19 pandemic has disproportionately placed on women, highlights the need for their good vision care.

“This resolution is a much-needed step to ensure that good vision is accessible to all,” says Kristan Gross, Global Executive Director, Vision Impact Institute. “As vision advocates, we have worked for years in partnership with others to ensure that vision is pivotal in the global development conversation. This unanimous decision is a testimony to the power of partnerships and coalitions that believe good vision is key to unlocking human potential.”

###

About the Vision Impact Institute (VII)
The VII’s mission is to raise awareness of the importance of vision correction and protection to make good vision a global priority. Its Advisory Board is comprised of four independent international experts: Pr. Clare Gilbert (United Kingdom), Mr. Allyala Nandakumar (United States),   Dr. Serge Resnikoff (Switzerland), and Dr. Wang Wei (China).

The Vision Impact Institute is a registered 501(c)(3) non-profit organization, which receives support from the Vision for Life Fund from Essilor, the world leader in ophthalmic optics. The Vision Impact Institute hosts a unique database of research at  visionimpactinstitute.org .

Contact:
Andrea Kirsten-Coleman
Global Communications Manager
andrea.kirsten@visionimpactinstitute.org

Logo – https://mma.prnewswire.com/media/832635/Vision_Impact_Institute_Logo.jpg

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines

Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.

HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.¹ To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.

Ursula Belinda Myles, General Manager of Takeda’s Access Market Cluster (covering much of Africa) commented: “Africa’s underlying burden of endemic diseases is one of the largest in the world, and infectious diseases play a larger portion of these diseases across the continent. Like many other nations, COVID-19 has emphasized Africa’s greatest challenges around healthcare and highlighted the need for continued greater investment in healthcare systems. These investments are critical to secure economic development as Africa implements flagship projects around the 2030 Africa Health Strategy.”

Ursula added: “The announcement of our partnership with Frazier Healthcare Partners will allow Takeda to focus efforts and resources on vaccines for diseases prevalent across Africa and provide support in alleviating the growing burden that infectious diseases have on public health systems.”

Norovirus is a common intestinal infection marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.² Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.³ It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year with significant additional economic and social burden.³ No vaccines are currently approved for norovirus infection, and HIL-214 continues to be the most advanced norovirus vaccine candidate in human clinical trials.

“Takeda and Frazier have a history of successfully partnering together, and we are confident in HilleVax’s capabilities to progress HIL-214, the most advanced norovirus vaccine candidate in development with the potential to address the huge global burden of norovirus-associated acute gastroenteritis,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “This will allow Takeda to focus its efforts and resources on our dengue vaccine, which we have begun filing for licensure around the world, our pandemic programs, and our partnership with the US Government to develop a Zika vaccine

 Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, pandemic influenza and Zika. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development and manufacturing to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.

About HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates.  Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 CONTACTS:

Takeda Media Contacts:
Japanese Media Ryoko Matsumoto ryoko.matsumoto@takeda.com +81 (0) 3-3278-3414	edia Outside Japan Amy Atwood amy.atwood@takeda.com +1-774-571-3316
For HilleVax, Inc.:	For Frazier Healthcare Partners:
David Socks info@hillevax.com +1-650-325-5156	Liz Park liz.park@frazierhealthcare.com +1-650-319-1831

References

¹ Sherwood J, et al. Vaccine 2020; 38(41):6442-6449

² https://ww.cdc.gov/norovirus/index.html [accessed 2021 April 27].

³ Hall AJ, et al. Expert Rev Vaccines 2016;15(8):949-951

Mohammed Al Nasseri
Takeda Pharmaceuticals
+971507694646
Mohammed.alnasseri@fleishman.com